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Despite the current therapeutic options, filamentous fungal infections are associated with high mortality 
rate especially in immunocompromised patients. In order to find a new potential therapeutic approach, the 
in vitro inhibitory effect of two antiarrhythmic agents, diltiazem and verapamil hydrochloride were tested 
against different clinical isolates of ascomycetous and mucoralean filamentous fungi. The in vitro combi-
nations of these non-antifungal drugs with azole and polyene antifungal agents were also examined. 
Susceptibility tests were carried out using the broth microdilution method according to the instructions of 
the Clinical and Laboratory Standards Institute document M38-A2. Checkerboard microdilution assay 
was used to assess the interactions between antifungal and non-antifungal drugs. Compared to antifungal 
agents, diltiazem and verapamil hydrochloride exerted a relatively low antifungal activity with high 
minimal inhibitory concentration values (853–2731 μg/ml). Although in combination they could increase 
the antifungal activity of amphotericin B, itraconazole and voriconazole. Indifferent and synergistic inter-
actions were registered in 33 and 17 cases, respectively. Antagonistic interactions were not revealed 
between the investigated compounds. However, the observed high MICs suggest that these agents could 
not be considered as alternative systemic antifungal agents.
Keywords: Diltiazem hydrochloride – verapamil hydrochloride – antifungal activity – drug combinations 
– synergistic interaction
INTRODUCTION
Filamentous fungi could be responsible for severe, opportunistic, life-threatening 
infections, especially among immunocompromised organ transplant and cancer 
patients [18]. Although the genus Aspergillus still remains the most common cause of 
invasive mould infections, non-Aspergillus moulds, such as Fusarium and 
Scedosporium species and members of the order Mucorales are also reported as 
emerging human pathogens in recent years [6, 19, 26]. Conventional antifungal drugs 
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applied in clinical practice often have limited activity against these pathogens [7]. 
Moreover, their long-term use may cause severe adverse effects in the patients. 
According to the recent studies, more than 1.6 million people die of a serious fungal 
infection each year despite the currently available antifungal treatments [9]. These 
facts underline the importance of developing novel, safely applicable antifungal 
therapeutic strategies.
Based on previous studies, several non-antifungal medications possess secondary 
antifungal activity in vitro. Calcium channel blockers (CCBs), which are commonly 
used as antiarrhythmic drugs, block the Ca2+ influx influencing the calmodulin system 
of the cell, which modulates metabolism and growth [1]. Verapamil hydrochloride 
(VHC) is a phenylalkylamine CCB, exerts inhibitory effect on Candida and Asper-
gillus species (Table 1) [2, 28, 29]. Diltiazem hydrochloride (DHC) belongs to the 
benzothiazepine class of CCBs and it is able to increase the sensitivity of Candida 
albicans to fluconazole (FLC) (Table 1) [4]. These non-antifungal drugs, as mono-
therapeutic agents or in combination with conventional antifungals could serve as a 
potential basis for a novel therapeutic approach.
Considering the above-mentioned arguments, the objectives of the present work 
were (i) to examine and compare the in vitro antifungal effect of two CCBs (i.e., DHC 
and VHC) and conventional antifungal drugs (i.e., amphotericin B, AmB; FLC; itra-
conzole, ITC; ketoconazole, KTC; terbinafine, TRB; and voriconazole, VRC), and 
(ii) to investigate their in vitro combinations against clinical isolates of ascomycetous 
and mucoralean fungi.
MATERIALS AND METHODS
Strains
Ten ascomycetous and mucoralean fungal strains from different human infections 
were involved in the present study: Aspergillus fumigatus (Szeged Microbiology 
Collection, Szeged, Hungary; SZMC 2394 from keratitis), a member of the Fusarium 
solani species complex (SZMC 11412 from keratitis), Scedosporium aurantiacum 
(Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands; CBS 136046 
from lung infection), Scedosporium boydii (CBS 120157 from lung infection), 
Trichoderma longibrachiatum (Devonian Botanic Garden, University of Alberta 
Herbarium and Microfungus Collection, Edmonton, Alberta, Canada; UAMH 7955 
from sinus infection), Lichtheimia corymbifera (SZMC 95033 from lung infection), 
Rhizopus microsporus var. rhizopodiformis (CBS 102277 from rhinocerebral infec-
tion), Rhizomucor miehei (CBS 360.92 from kidney and liver infection), Rhizopus 
oryzae (CBS 146.90 from soft palate infection), and Rhizomucor pusillus (Swiss 
Federal Institute of Technology Culture Collection, Zurich, Switzerland; ETH M4920 
from tracheal discharge). All the isolates were maintained on malt extract agar (MEA, 
Biolab) slants.
Antifungal activity of calcium channel blockers 337
Acta Biologica Hungarica 68, 2017
Susceptibility testing
The in vitro minimal inhibitory concentration (MIC) values were determined using 
the broth microdilution method following the guidelines described in the CLSI M38-
A2 document [5].
The antifungal effect of two CCBs (i.e., DHC and VHC [Sigma-Aldrich]) and 
seven clinically used antifungal agents (i.e., AmB [Medispec Pharmaceuticals Pvt. 
Ltd], FLC [Molekula Ltd.], CLT, ITC, KTC, TRB [Sigma-Aldrich], and VRC [Pfizer 
Inc.]) was investigated and compared. Stock solutions of non-antifungal agents were 
prepared in sterile distilled water, while antifungal agents were dissolved in the sol-
vents recommended by CLSI M38-A2 document [5]. Further dilutions were prepared 
in the testing medium, RPMI-1640 buffered to pH 7.0 with 0.165 mol/l 
3-[N-morpholino] propanesulfonic acid (Sigma-Aldrich). The final concentration 
ranges were 128–4096 µg/ml for CCBs and 0.25–128 µg/ml for antifungal drugs. 
Considering the speeds of germination and growth, microtiter plates of mucoralean 
fungi were evaluated after 24 hours, whilst Aspergillus, Fusarium and Trichoderma 
strains after 48 hours, and Scedosporium strains after 72 hours of incubation at 37 °C. 
Results were read using a microplate reader in well-scanning mode (SPECTROstar 
Nano, Germany). Untreated control samples served as growth controls and we take 
their absorbance (OD620) as 100%. MIC was defined as the lowest concentration of 
the tested compound that totally inhibited the growth of the fungus on the basis of the 
OD620 values as compared to the untreated control.
Combination tests
Interactions were investigated between CCBs and AmB, ITC, and VRC using the 
checkerboard microdilution method [8]. Interactions between VHC and AmB were 
not tested, since according to the drug information leaflet provided by the manufac-
turer, the co-administration of these two drugs should be avoided. The final concen-
tration ranges of each drug were chosen based on the MIC data obtained by the 
antifungal susceptibility tests. Fractional inhibitory concentration index (FICI) values 
were calculated to describe the interactions between the compounds as described 
previously [11]. Synergism was defined as FICI ≤ 0.5, indifference as 0.5 < FICI ≤ 4, 
and antagonism was defined when FICI was > 4 [22].
RESULTS
Susceptibility testing
Results of the susceptibility tests are presented in Table 2. In general, the MICs of 
DHC and VHC were quite high, but mucoralean isolates (MIC range: 853–2048 µg/
ml) proved to be slightly more susceptible to these non-antifungal drugs than the 
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ascomycetous isolates (MIC range: 1024–2731 µg/ml). Differences in the susceptibil-
ity to antifungal drugs were also observed between the two groups: while VRC was 
more effective against ascomycetous fungi, mucoralean fungi proved to be more 
susceptible to AmB, ITC and KTC. Against the investigated Ascomycetes, KTC 
proved to be the most effective antifungal drug (MIC range: 2–24 µg/ml), followed 
by VRC (MIC range: 16–53 µg/ml). MICs of ITC were generally high, but A. fumi-
gatus SZMC 2394 (MIC: 2 µg/ml) was susceptible to it. AmB and KTC proved to be 
the most effective antifungals against mucoralean isolates with MICs ranging 
between 0.04–1.33 µg/ml and 0.5–2 µg/ml, respectively. The growth of mucoralean 
fungi was also inhibited by low concentrations of CLT (MICs < 0.25 µg/ml) and TRB 
(MIC range: 0.3–4 µg/ml), except the case of R. oryzae CBS 146.90, where the MICs 
of 64 µg/ml for CLT and > 28 µg/ml for TRB were recorded. With one exception 
(S. aurantiacum CBS 136046, MIC: 64 µg/ml), FLC was ineffective against all iso-
lates in the investigated concentration range. Summarizing, conventional antifungal 
drugs proved to be more effective than CCBs.
Combination tests
The results of the combination tests are summarized in Tables 3 and 4. Compared to 
the single use, the relatively high MIC values (853–2731 µg/ml) of CCBs decreased 
or remained the same in the combination tests (MIC range: 32–> 2048 µg/ml). 
Antagonistic interactions were not detected between the investigated compounds. 
Synergistic and indifferent interactions were revealed in 17 and 33 cases, respec-
tively. Between VHC and VRC, and DHC and VRC only indifferent interactions were 
observed; while the interactions of CCBs with ITC were synergistic in most cases. 
Between AmB and DHC no interactions were revealed against all mucoralean iso-
lates, while against ascomycetous fungi synergistic and indifferent interactions were 
registered in three and two cases, respectively.
DISCUSSION
The antifungal effect of CCBs has been investigated previously against Candida and 
Aspergillus species, but data on its effect against other human pathogenic ascomyce-
tous and mucoralean fungi are not reported in the literature (Table 1). Basically, our 
results are in agreement with these reports: relative high concentrations of DHC and 
VHC inhibited the growth of the investigated fungal strains, MICs were between 853 
and 2731 μg/ml (Table 2). These values are much higher than their therapeutically 
available plasma levels (Table 1). Khalaf et al. [12] observed a much broader and 
higher MIC range (10,000–50,000 μg/ml) for Aspergillus and Candida strains. 
Afeltra et al. [2] reported that VHC was inactive against Aspergillus fumigatus (MIC 
> 640 μg/ml). In another study, Aspergillus parasiticus also proved to be resistant to 
VHC and DHC, but their applied concentrations (<490 μg/ml and <450 μg/ml, 
340 Mónika HoMa et al.
Acta Biologica Hungarica 68, 2017
Isolate
Antifungal agent/MIC values (µg/ml)a
FICIb Interactionc
DHCalone DHCin combination VRCalone VRCin combination
Ascomycetous fungi
A. fumigatus 2731 2048 16 4 1.00 NI
F. solani 2048 2048 53 4 1.08 NI
S. aurantiacum 2048 2048 16 1 1.06 NI
2048 128 16 16 1.06 NI
S. boydii 2048 128 16 8 0.56 NI
T. longibrachiatum 1707 128 53 32 0.68 NI
Mucoralean fungi
L. corymbifera 2048 2048 171 256 2.50 NI
R. microsporus 2048 2048 107 8 1.07 NI
R. miehei 1024 1024 128 8 1.06 NI
R. oryzae 1707 2048 85 8 1.29 NI
R. pusillus 1024 2048 85 8 2.09 NI
Table 3
In vitro antifungal activity of diltiazem hydrochloride in combination with conventional antifungal 
agents against ascomycetous and mucoralean fungal strains
Isolate
Antifungal agent/MIC values (µg/ml)a
FICIb Interactionc
DHCalone DHCin combination AmBalone AmBin combination
Ascomycetous fungi
A. fumigatus 2731 2048 2 2 1.75 NI
F. solani 2048 256 8 2 0.38 S
S. aurantiacum 2048 512 128 16 0.38 S
2048 256 128 32 0.38 S
S. boydii 2048 32 64 8 0.14 S
T. longibrachiatum 1707 1024 2 0.5 0.85 NI
Mucoralean fungi
L. corymbifera 2048 2048 0.09 0.015 1.17 NI
R. microsporus 2048 1024 1.3 0.25 0.69 NI
R. miehei 1024 128 0.04 0.06 1.63 NI
R. oryzae 1707 256 0.17 0.25 1.62 NI
R. pusillus 1024 2048 0.05 0.001 2.02 NI
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respectively) could inhibit the aflatoxin production of this strain [24]. VHC inhibited 
the adhesion, gastrointestinal colonization and the oxidative stress response of 
C. albicans and significantly decreased the hyphal development in a concentration of 
≥10 μg/ml [28, 29].
Our findings on the interactions between CCBs and conventional antifungal drugs 
are comparable to previously reported observations. We proved that DHC and VHC 
could interact synergistically with azoles and polyene antifungals (Tables 3, 4). While 
in these tests the MICs of non-antifungal drugs were still beyond their in vivo achiev-
able plasma concentrations, the MICs of AmB, ITC and VRC could be decreased to 
their therapeutic plasma levels [3, 10, 16].
Krajewska-Kułak and Niczyporuk [14] reported that VHC and other CCBs 
increased the antifungal activity of ketoconazole against C. albicans strains in vitro 
and found synergistic effect between them. Afeltra et al. [2] observed no interaction 
between VHC and ITC against A. fumigatus. The sensitivity of C. albicans to FLC 
was increased dramatically in the presence of DHC and VHC [4]. Other calcium 
channel antagonists were tested by Liu et al. [17] against FLC-resistant Candida 
strains. All the CCBs exhibited no antifungal activity with MICs >512 μg/ml, 
Table 3 (cont.)
Isolate
Antifungal agent/MIC values (µg/ml)a
FICIb Interactionc
DHCalone DHCin combination ITCalone ITCin combination
Ascomycetous fungi
A. fumigatus 2731 128 2 0.5 0.30 S
F. solani 2048 >2048 >128 >128 >0.50 NI
S. aurantiacum 2048 128 128 8 0.13 S
S. boydii 2048 128 32 2 0.13 S
T. longibrachiatum 1707 1024 >128 1 >0.50 NI
Mucoralean fungi
L. corymbifera 2048 128 2 0.25 0.19 S
R. microsporus 2048 2048 5 0.03 1.01 NI
R. miehei 1024 128 2 0.5 0.38 S
R. oryzae 1707 128 8 1 0.20 S
R. pusillus 1024 128 3 0.25 0.21 S
aMIC – minimum inhibitory concentration; DHCalone, AmBalone, ITCalone and VRCalone – mean MICs of 
diltiazem hydrochloride, amphotericin B, itraconazole, and voriconazole, respectively, when applied alone; 
DHCin combination, AmBin combination, ITCin combination, and VRCin combination, mean MICs of diltiazem hydrochloride, 
amphotericin B, itraconazole, and voriconazole, respectively, when applied in combination.
bFICI – fractional inhibitory concentration index.
cS – synergism (FICI ≤ 0.5); NI – no interaction (0.5 < FICI ≤ 4) [22].
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Table 4
In vitro antifungal activity of verapamil hydrochloride in combination with conventional antifungal 
agents against ascomycetous and mucoralean fungal strains
Isolate
Antifungal agent/MIC values (µg/ml)a
FICIb Interactionc
VHCalone VHCin combination VRCalone VRCin combination
Ascomycetous fungi
A. fumigatus 2731 2048 16 4 1.00 NI
F. solani 2048 2048 53 4 1.08 NI
S. aurantiacum 1024 128 16 8 0.63 NI
S. boydii 2048 128 16 8 0.56 NI
T. longibrachiatum 2048 128 53 32 0.67 NI
Mucoralean fungi
L. corymbifera 2048 2048 171 8 1.05 NI
R. microsporus 1024 1024 107 8 1.07 NI
R. miehei 853 256 128 64 0.80 NI
R. oryzae 1024 1024 85 8 1.09 NI
R. pusillus 1024 1024 85 8 1.09 NI
Isolate
Antifungal agent/MIC values (µg/ml)a
FICIb Interactionc
VHCalone VHCin combination ITCalone ITCalone
Ascomycetous fungi
A. fumigatus 2731 128 2 0.5 0.30 S
F. solani 2048 2048 >128 >128 2.00 NI
S. aurantiacum 2048 256 128 16 0.25 S
S. boydii 2048 128 32 2 0.13 S
T. longibrachiatum 2048 1024 >128 4 >0.50 NI
Mucoralean fungi
L. corymbifera 2048 128 2 0.125 0.13 S
R. microsporus 1024 128 5 1 0.33 S
R. miehei 853 64 2 0.25 0.20 S
R. oryzae 2048 1024 8 0.25 0.53 NI
R. pusillus 1024 64 3 0.125 0.10 S
aMIC – minimum inhibitory concentration; VHCalone, AmBalone, ITCalone, and VRCalone – mean MICs of 
verapamil hydrochloride, amphotericin B, itraconazole, and voriconazole, respectively, when applied alone; 
VHCin combination, AmBin combination, ITCin combination, and VRCin combination, mean MICs of verapamil hydrochloride, 
amphotericin B, itraconazole, and voriconazole, respectively, when applied in combination.
bFICI – fractional inhibitory concentration index.
cS – synergism (FICI ≤ 0.5); NI – no interaction (0.5 < FICI ≤ 4) [22].
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although, in combination with FLC, strong synergistic interactions were revealed. 
Moreover, Pina-Vaz et al. [23] observed that FLC resistance of Candida strains could 
be efficiently reverted by the application of VHC.
As CCBs affect all eukaryotic cells, their potential clinical use as antifungal agents 
must be clarified by further studies. The influence of DHC and VHC on human peri-
toneal polymorphonuclear cells and monocytes were investigated by Levy et al. [15]. 
The authors reported that these CCBs significantly reduced the bactericidal and fun-
gicidal activity of phagocytic cells in vitro, however in vivo this effect was not 
observed. In addition to this, CCBs are both substrates and inhibitors of the cyto-
chrome P450 family CYP3A4. Their co-administration with other drugs that share the 
CYP3A4 pathway (e.g. azoles) may alter the pharmacokinetic properties and increase 
the plasma levels of both drugs [20]. Optimal therapeutic drug-level monitoring and 
dosage adjustments may also be necessary during therapy to avoid serious side 
effects.
In conclusion, the in vitro sensitivity of both ascomycetous and mucoralean fungi 
to azoles and AmB could be increased with the addition of DHC and VHC in the test-
ing media. However, their observed high MIC values and low therapeutic plasma 
level suggest that these agents could not be administered systemically. A possible 
limitation of our study is that one isolate per species was investigated only, however 
antifungal susceptibility might vary among different isolates of the same species.
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